Panacea Biotec Resolves AY 2016-17 Tax Demand, ₹10.23 Crore Liability Nil

Panacea Biotec Ltd's tax liability for Assessment Year (AY) 2016-17 has been reduced to Nil following a rectified Income Tax Assessment Order. The company had faced an initial demand of approximately ₹10.23 Crore, which has now been canceled by the tax authorities.

Tax Order Update

Panacea Biotec announced on April 7, 2026, that it received a rectified Income Tax Assessment Order for Assessment Year 2016-17 on April 6, 2026. This order replaces a previous demand notice issued on March 1, 2026.

The rectified order confirms the final tax liability for AY 2016-17 as Nil (₹0.00 crore), canceling the initial tax demand of roughly ₹10.23 Crore.

The company expects no negative financial or operational impact from this resolution.

Financial Clarity Gained

This resolution provides financial certainty for Panacea Biotec regarding its tax obligations for AY 2016-17, removing a potential financial burden.

Background on Tax Issues

Panacea Biotec, a biotechnology and pharmaceutical company, has faced several tax disputes. In early March 2026, the company received an income tax demand order of ₹10.23 Crore for AY 2016-17, related to disputed expenses.

Around the same time, Panacea Biotec also faced a ₹45.71 Crore tax demand for AY 2015-16. Earlier in March 2026, the Income Tax Appellate Tribunal (ITAT) canceled a ₹329.49 Crore tax demand for assessment years 2005-06 to 2012-13.

In late March 2026, appeals against tax penalty orders totaling ₹9.38 Crore were dismissed by the Commissioner of Income Tax (Appeals). Panacea Biotec disputes these findings and plans further appeals.

Immediate Impact

• The ₹10.23 Crore liability for AY 2016-17 is officially removed.
• The company gains greater financial certainty on past tax assessments.

Ongoing Tax Concerns

While this tax demand is resolved, Panacea Biotec faces other tax litigations. The dismissed appeals totaling ₹9.38 Crore for penalties on alleged income under-reporting remain an ongoing legal challenge. Investors will monitor these developments.

Industry Tax Landscape

Tax and regulatory matters are frequent in the pharmaceutical sector. For example, Divi's Laboratories Ltd. is contesting tax adjustments on transfer pricing and corporate tax. AstraZeneca Pharma India received a mixed ruling from the ITAT, with relief on corporate tax but a referral back for transfer pricing issues for AY 2017-18 and 2018-19. These examples show the challenging tax environment for Indian pharma companies.

Investor Focus

• Further developments in Panacea Biotec's other tax disputes and appeals.
• Any new company filings or communications regarding tax matters.
• The company's financial performance as it resolves past tax liabilities.